SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data

Novo Nordisk

Status: Completed

Conditions: Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD)

Treatments: Other: No tretament given

Study type: Observational

Funder types: Industry

Identifiers

NCT06769646

U1111-1313-1011 (Other Identifier)

DAS-8385

Details and patient eligibility

About

This study is being carried out in 4 countries (France, Italy, Spain and the UK) to understand the clinical care pathway of population living with type 2 diabetes who also have evidence of chronic kidney disease.

The primary objective is to describe the population with T2D and CKD in terms of demography, clinical characteristics and medication use by CKD stage.

Enrollment: 110,074 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Adults (18 years old or older) diagnosed with T2D and treated with an antidiabetic medication before or at index date, set up on 1 January 2021

2. With evidence of Kidney damage before or at index date:

   1. diagnosed with CKD
   2. or with a record of eGFR below 60 ml/min/1.73 m^2
   3. or with a record of uACR above 30 mg/g

3. Consulting a GP (all countries) or an Endocrinologist (France, Spain, Italy) or a Nephrologist (Spain) of the THIN® network.

Exclusion criteria

1. aged less than 18 years old at index date
2. less than 360 days prior index date
3. less than 360 days after index date

Trial design

110,074 participants in 1 patient group

People with T2D in THIN databases

Description:

Individuals from the THIN® France, THIN® Italy, THIN® Spain and THIN® UK databases living with T2D and CKD

Treatment:

Other: No tretament given